Member Info for jimbogains

Big investor reducing its position in EUDA, not sure I like it:

————

Hudson Bay Capital Management LP Sells 760,500 Shares of EUDA Health Holdings Limited (NASDAQ:EUDA)

Do we know if Adam is part of the gang that sought to oust certain board members or not?

If not, and given his silence and lack of any material sell-down of his holding, I wonder what he might know that we don’t.

I still have a tiny bit of hope… it’s very little though

Starting to think my 31 March prediction for EUDA merger might be wide of the mark. My £25k in is now a bit over £3k. Whoops.

Any other crazy investment ideas to sink my cash into? I’m bored with this one

Are we expecting an update from management any time soon? Any q&as in the diary?

Interesting find, Badsterman... worth pointing out that these are different to the notes expected to be converted at 31 March 2024. These ones would have converted at $5 per share, which would presumably have been very bad news for the holder had they decided to convert (given share price is so much lower)

I'm amazed that EUDA has not been required to post any sort of market update on the TRx merger, given the previous announcement (along with timeframe) was quite a significant factor in the increase in its share price. Logically, the negotiations have to be ongoing in some shape or form, otherwise there would be an announcement... but I suppose there's a bigger question as to whether they have hit a dead-end in their negotiations.

Really hope there will be an update soon, so I (and others) can make an informed decision about what to do with shares and votes.

Honestly, all this FCA stuff is nonsense. We have made bets in a risky company and it hasn’t yet worked out. Nobody is going to be paying us compensation if it fails. Live and learn and, in the meantime, hope that 201 comes good.

Tanvier Malik seems to be behind Sanderson:

https://www.theinvestmentobserver.co.uk/companies/2018/03/12/beaufort-securities-scandal/

To be fair NH, that's quite an impressively low number of trades! Guess everyone's waiting to see what Suzy's response to the shareholders will be before selling or buying.

Was anticipating a big swing either way in the share price today, but it's pretty meh.

I do think Suzy has been naive in her approach to TRx, but I entirely disagree with the posters implying she's a swindler. Identification of new drugs is a business which will only burn cash unless/until an asset is monetised... clearly disappointing that VAL hasn't done that yet, but that really is the business model. The only hope (outside of drug monetisation) for cash coming in is the lab. If people don't understand this, they really shouldn't be invested in this share.

Fair enough all. The shareholders have taken action and I assume that a vote will therefore go ahead. I would just ask that the relevant shareholders now constructively engage with the BOD to determine whether the vote should happen either (I) ASAP, to resolve uncertainty in the TRx relationship; or, failing that, (ii) 1 April.

I don’t see any point in stringing this out long after the end of March.

Agreed NH, there is no 31 March deadline we are aware of. That said, if the merger does not complete by then, EUDA’s convertible loan notes suddenly become very expensive.

My nervousness is around the interdependencies here. If Val201 is an important reason for the merger, then uncertainty around whether any future board will pull out of the Val201 deal could mean that the merger cannot complete until the VAL board vote concludes. However, the board vote will likely be for Suzy to stay only if the merger goes ahead.

So, my concern is that by taking action now, the VAL shareholders may have scuppered the deal. Timing not sensible in my view

It does make me nervous that this is happening such a short time before the apparent deadline for EUDA-TRx merger. If (big if) that goes ahead by 31 March, I wonder how the uncertainty of any vote could impact on that relationship

Flip-side, I guess, is that this sends a strong message to TRx that the time for waiting is over. Does anyone have a view on how quickly a vote might take place? April Fools Day would frankly be perfect

Out of interest, did Stella jump ship before or after it was decided that directors wouldn't be getting more share options?

To be fair to her, she did acquire some shares around the same time, so must presumably have faith in the business.

Would it be feasible for the company to just sell its assets as they stand?

Presumably there is some easily realisable value in the biobank and some of the fixed assets and, if (!) they could be sold at fair market value, the company's interests in 201, 301, CLX, etc could hopefully provide some sort of cash to the shareholders.

In essence, if 201 doesn't complete (and assuming that means Suzy goes), could a newly appointed CEO realise substantially more then the current £6.3m market cap for flogging off the family silver?

I'm still hopeful on 201. We should know definitively what the TRx-EUDA outcome looks like in a bit over seven weeks... at which point the shareholders will need to make an informed decision about what comes next, i.e. (i) divest; (ii) change Board; or (iii) continue with the status quo. There's probably a fourth and fifth etc option but you get the picture.

Still not clear what the options are, though. If no 201 monies by end of March, the shareholders will be rightly annoyed and I can't see Suzy surviving. In that circumstance, what do you think the new CEO should do? Lab isn't generating cash quickly enough to sustain the business, but terminating the lab would be even more wasteful. We have legacy assets such as 201 which nobody seems particularly interested in. And the investment in identifying new products requires cash which us shareholders need to stump up.

Not sure where we go.

Suzy must really believe that the TRx merger will soon complete and 201 monies then received, otherwise her spending plans do not make any sense. That said, if 201 monies are not received by 31 March, she surely can't stay in post - she has had some time now to implement the TCRO strategy (but it still appears to be a cash negative offering without any immediate promise) and all the rest of the potential value lies in legacy assets. Question is, what are the options for the business is Suzy goes?

I know a lot of shareholders see Adam's appointment to the board as a panacea, but in reality he is (was?) fully bought into the TCRO strategy and i'm not sure what alternative direction he would provide.

Which leaves... carrying on doing more of the same (which frankly might as well have Suzy in charge) or... liquidating the assets?

I don't know. Where do we really go next?

Wasn’t it Adam pushing for Valirx to be a TCRO to begin with? Success in this field will take time. I can’t imagine that he would bother with all the shareholder aggro for… what? Nothing in it for him and I’m guessing he has no desire to sit on the board.

That's really insightful, thanks Badsterman. Quite expensive financing, given the loan notes convert at $1 per share (compared to $1.61 overnight). I assume the cash is required to keep the deal advisers on board. Interesting that there's two dates of 31 January and 31 March - I assume the idea is that they get the TRx deal done (and cash flows in) by 31 January, but if it doesn't, more will be lent to EUDA to keep the deal advisers going.

Not been any comment from Adam in a while. Any idea where he’s got to?